Clinical trials: Fat Disorder
Hyperlipidemia
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in…
- Trial name
- NCT02659397
- Testing
- ETC-1002, Atorvastatin
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Esperion Therapeutics, Inc.
Type 1 Diabetes
Evaluation of Fats on Postprandial Glucose Control
The purpose of this study is examine the effect of different fat types on postprandial glucose control in patients with type 1 diabetes.
- Trial name
- Nabucco (NCT01869790)
- Testing
- Different fat types
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Joslin Diabetes Center
Visceral Fat, Insulin Resistance
Study of Visceral Fat in type2diabetic Patients and Its Relation to Microvascular Complications
Study the correlation between METS IR and visceral fat in type 2 diabetes and its relation to microvascular complication
- Trial name
- NCT06112197
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Cervical Cancer
Fat Grafting for Vaginal Stenosis in Gynaelogical Cancer
The GRASS study looks at performing a technique called "Fat Tissue Grafting" to assess whether it can reduce the side effects of vaginal stenosis effects and improve the sexual function of participants who wish to preserve…
- Trial name
- GRASS (NCT06015360)
- Testing
- Fat Graft
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prediabetes, Type 2 Diabetes
Beta Cell Restoration Through Fat Mitigation
Weight loss achieved through gastric banding will be superior to treatment with metformin in preserving or restoring pancreatic beta cell function in people with prediabetes or mild type 2 diabetes.
- Conditions
- Prediabetes, Type 2 Diabetes, Obesity
- Trial name
- BetaFat (NCT01763346)
- Testing
- Metformin, gastric banding
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Southern California
Obesity, Pre-diabetes
SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue.
- Trial name
- NCT04907214
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Vanderbilt University Medical Center
Hypertriglyceridemia
Characterization of Fatty Acid Composition of Triglycerides in Patients With Hypertriglyceridemia-induced Acute Pancreatitis
) Finding a unique pattern in the triglyceride composition of patients with hypertriglyceridemia that increases the chances of getting pancreatitis and which can serve as a laboratory predictive tool for patients and define them…
- Trial name
- NCT04097990
- Testing
- blood sample
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Type 2 Diabetes
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with established lipid-lowering therapy in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00251680
- Testing
- Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy
- Where
- 77 sites in United States, Czechia and 7 more
- Volunteers
- 400 people
- Sponsor
- Takeda
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency
The purpose of this study is to evaluate the efficacy in patients with cystic fibrosis and pancreatic insufficiency following treatment with BSSL
- Trial name
- NCT00743483
- Testing
- rhBSSL
- Where
- 4 sites in Netherlands, Poland
- Volunteers
- 15 people
- Sponsor
- Swedish Orphan Biovitrum
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Hypercholesterolemia, Combined Hyperlipidemia
Cholesterol-Lowering Effects of Policosanol
Despite undeniable progress in the reduction of morbidity and mortality of coronary heart disease (CHD) prevention is a mainstay for medical intervention.
- Trial name
- NCT00288483
- Testing
- Policosanol
- Sponsor
- Drug Commission of the German Medical Association
Juvenile Neuronal Ceroid Lipofuscinosis
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
The purpose of this study is to evaluate the safety and efficacy of multiple doses of PLX-200 in patients with CLN3 disease.
- Trial name
- NCT04637282
- Testing
- PLX-200
- Sponsor
- Polaryx Therapeutics, Inc.
Acute Respiratory Distress Syndrome, Ards
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
This is a Phase 2 randomized study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for subjects hospitalized subjects with acute respiratory distress syndrome not related to…
- Trial name
- NCT04909879
- Testing
- COVI-MSC
- Sponsor
- Sorrento Therapeutics, Inc.
Obesity
The Incidence and Factors of Brown Adipose Tissue in Chinese
Previous studies have shown active brown adipose tissue (BAT) is present in adults and may play important roles in regulating energy homeostasis.
- Trial name
- NCT01381042
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Huashan Hospital
Cardiovascular Disease, Hypertension
Unmet Social Needs Study
The impacts of unmet social needs, such as homelessness, inconsistent access to food, and exposure to violence on health are well-established, especially for cardiovascular disease.
- Conditions
- Cardiovascular Disease, Hypertension, Diabetes Mellitus, Hyperlipidemia
- Trial name
- NCT04977583
- Testing
- Unmet Need Screening, Unmet Need Referral - Resource Sheet, Unmet Need Referral Assistance
- Where
- 3 sites in United States
- Volunteers
- 479 people
- Sponsor
- VA Office of Research and Development
Hypercholesterolemia
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
Evaluation of the clinical profile (lipid efficacy, safety and PK) across a number of doses of CIVI 007, a PCSK9 inhibitor. Patients to be evaluated will be on a stable background of statin therapy with or without ezetimibe.
- Trial name
- NCT04164888
- Testing
- CIVI 007
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Civi Biopharma, Inc.
Dyslipidemia
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia.
- Trial name
- PURSUIT (NCT06173570)
- Testing
- AZD0780
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 428 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
Rebalancing the Fat Content of the Heart and Muscles
Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results.
- Trial name
- Re-CHARM (NCT07065383)
- Testing
- Semaglutide administration plus dietary counselling and physical activity encouragement, Semaglutide plus a personalised and supervised program of resistance and endurance training
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Aberdeen
Hypertriglyceridemia
Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia
This study is to evaluate the efficacy and safety of ARI-3037MO 3g BID compared to placebo in reducing triglyceride (TG) levels of subjects with severe (≥500 mg/dL and <2,000 mg/dL) hypertriglyceridemia.
- Trial name
- NCT02250105
- Testing
- ARI-3037MO
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Arisaph Pharmaceuticals Inc
Familial Hypercholesterolemia
Improving Identification of Familial Hypercholesterolaemia in Primary Care (FAMCAT)
Multi-centre, non-randomised, non-controlled quasi-experimental study with nested qualitative study and economic appraisal. Improving the identification of patients at high risk of cardiovascular disease in primary care, caused…
- Trial name
- FAMCAT (NCT03934320)
- Testing
- FAMCAT
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Nottingham